Faculty of Pharmacy and Pharmaceutical Sciences,University of Alberta,Edmonton,Alberta,Canada.
Can J Neurol Sci. 2017 Nov;44(6):643-653. doi: 10.1017/cjn.2017.206.
Seizures are important complications following a subarachnoid hemorrhage (SAH). The evidence for the use of antiepileptic drugs (AEDs) in treatment and prevention of those seizures is conflicting. The purpose of this review is to provide an up-to-date evidence summary of the incidence and outcomes of seizures following an SAH as well as the use of different AEDs post-SAH in order to evaluate the need for seizure prophylaxis, the choice of AEDs, and their dosing considerations in SAH patients. A literature search of PubMed, Medline, Embase, and the Cochrane Library was performed. A total of 37 studies were reviewed, mostly observational. Definitions of seizures in temporal relation to initial hemorrhage were variable. Similarly, the rates of seizures varied in the literature, ranging from 0 to 31%. Given the reported adverse outcomes associated with AED usage, seizure prophylaxis is not warranted. Levetiracetam appears to be better tolerated than phenytoin in SAH patients, though further research is needed. Higher initial dosing of levetiracetam might be required due to its enhanced clearance in SAH patients. In conclusion, there is a lack of quality evidence to definitively recommend the use of one AED over another. Further prospective research comparing the use of different AEDs in patients with an SAH is needed.
癫痫发作是蛛网膜下腔出血(SAH)后的重要并发症。抗癫痫药物(AEDs)在治疗和预防这些癫痫发作中的应用证据存在争议。本综述的目的是提供关于 SAH 后癫痫发作的发生率和结果以及不同 AED 在 SAH 后的使用的最新证据总结,以评估癫痫预防的必要性、AED 的选择及其在 SAH 患者中的剂量考虑因素。对 PubMed、Medline、Embase 和 Cochrane 图书馆进行了文献检索。共审查了 37 项研究,主要是观察性研究。与初始出血时间相关的癫痫发作的定义各不相同。同样,文献中的癫痫发作率也各不相同,范围从 0 到 31%。鉴于与 AED 使用相关的不良后果,不需要进行癫痫预防。左乙拉西坦在 SAH 患者中的耐受性似乎优于苯妥英钠,但仍需要进一步研究。由于其在 SAH 患者中的清除率增强,可能需要更高的初始左乙拉西坦剂量。总之,缺乏高质量的证据来明确推荐使用一种 AED 而不是另一种。需要进一步开展比较不同 AED 在 SAH 患者中使用的前瞻性研究。